Scinai Immunotherapeutics (SCNI) EBT (2015 - 2026)

Scinai Immunotherapeutics has disclosed EBT across 12 years of filings, most recently posting -$2.1 million for Q2 2026.

• In Q2 2026, EBT rose 2.23% year-over-year to -$2.1 million; the TTM figure through Jun 2026 stood at -$8.4 million (down 289.12% YoY), while the FY2025 annual figure was -$9.7 million, down 12.82% from the prior year.
• EBT came in at -$2.1 million for Q2 2026 at Scinai Immunotherapeutics, up from -$2.5 million in the prior quarter.
• In the past five years, EBT ranged from a high of $14.4 million in Q3 2022 to a low of -$14.5 million in Q4 2022.
• Average EBT over 5 years is -$1.0 million, with a median of -$2.2 million recorded in 2025.
• Year-over-year, EBT surged 517.28% in 2022 and slumped 233.08% in 2023.
• Over 5 years, EBT stood at -$14.5 million in 2022, then surged by 61.94% to -$5.5 million in 2023, then surged by 59.06% to -$2.3 million in 2024, then grew by 3.0% to -$2.2 million in 2025, then climbed by 2.23% to -$2.1 million in 2026.
• Per Business Quant data, the three most recent EBT figures were -$2.1 million in Q2 2026, -$2.5 million in Q1 2026, and -$2.2 million in Q2 2025.